How the DRUG ETF fits into an ASX portfolio
The BetaShares DRUG ETF provides investors with exposure to leading global healthcare companies, hedged into Australian dollars.
DRUG could be used by investors looking for a tactical exposure to global healthcare companies, while reducing currency risk through hedging strategies.
DRUG meets our minimum level for FUM
The BetaShares DRUG ETF had $164.04 million of money invested when we last pulled the monthly numbers. Given DRUG’s total funds under management (FUM) figure is over $100 million, the ETF has met our minimum criteria for the total amount of money invested, otherwise known as FUM. We draw the line at $100 million for ETFs in the International shares sector because we believe that relative to smaller ETFs, achieving this amount of FUM de-risks the ETF.
What about management fees and costs?
BetaShares charges investors a yearly management fee of 0.57% for the DRUG ETF. This means that if you invested $2,000 in DRUG for a full year, you could expect to pay management fees of around $11.40.
For context, the average management fee (MER) of all ETFs covered by Best ETFs Australia on our complete list of ASX ETFs is 0.51% or around $10.20 per $2,000 invested. Keep in mind, small changes in fees can make a big difference after 10 or 20 years.
Next steps
Before buying any ETF based on what you read here on Best ETFs, check out our BetaShares DRUG report – it’s completely free! Then, search our complete list of ASX ETFs to do a proper side-by-side comparison of your chosen sector or thematic.
